Eurobio Scientific SA
PAR:ALERS

Watchlist Manager
Eurobio Scientific SA Logo
Eurobio Scientific SA
PAR:ALERS
Watchlist
Price: 25.35 EUR 0.2%
Market Cap: 253.6m EUR
Have any thoughts about
Eurobio Scientific SA?
Write Note

Eurobio Scientific SA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eurobio Scientific SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Eurobio Scientific SA
PAR:ALERS
Revenue
€144.2m
CAGR 3-Years
-13%
CAGR 5-Years
21%
CAGR 10-Years
17%
Valneva SE
PAR:VLA
Revenue
€229.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Revenue
€24.9m
CAGR 3-Years
-10%
CAGR 5-Years
-26%
CAGR 10-Years
11%
G
Genfit SA
PAR:GNFT
Revenue
€84m
CAGR 3-Years
151%
CAGR 5-Years
61%
CAGR 10-Years
29%
Inventiva SA
PAR:IVA
Revenue
€15.6m
CAGR 3-Years
255%
CAGR 5-Years
37%
CAGR 10-Years
N/A
OSE Immunotherapeutics SA
PAR:OSE
Revenue
€83.4m
CAGR 3-Years
83%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

Eurobio Scientific SA
Glance View

Market Cap
276.9m EUR
Industry
Biotechnology

Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.

ALERS Intrinsic Value
15.76 EUR
Overvaluation 38%
Intrinsic Value
Price

See Also

What is Eurobio Scientific SA's Revenue?
Revenue
144.2m EUR

Based on the financial report for Jun 30, 2024, Eurobio Scientific SA's Revenue amounts to 144.2m EUR.

What is Eurobio Scientific SA's Revenue growth rate?
Revenue CAGR 10Y
17%

Over the last year, the Revenue growth was 13%. The average annual Revenue growth rates for Eurobio Scientific SA have been -13% over the past three years , 21% over the past five years , and 17% over the past ten years .

Back to Top